个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
北京协和医院神经外科主任医师,教授,博士研究生导师。主要致力于恶性脑肿瘤的综合治疗和全病程管理,对恶性胶质瘤/转移瘤的手术、化疗、分子靶向治疗、免疫治疗、及耐药复发的治疗等有较深入的研究;在微创神经外科领域,开展多模式影像学融合(如PET/CT,fMRI, MRI, CT)的神经导航引导下的脑肿瘤切除,以及影像引导下-术中电生理检测下-唤醒麻醉下重要皮层及白质纤维束功能区病变切除。目前担任中国抗癌协会脑胶质瘤专业委员会主任委员,中国药促会脑神经药物专业委员会副主任委员,北京医学奖励基金会脑转移瘤专委会主任委员,中国脑转移瘤协作组副组长,曾任中国脑胶质瘤协作组第三任组长。现任中国现代神经疾病杂志编委,中华外科杂志,中华神经外科杂志,中华神经科杂志及中国神经精神疾病杂志审稿专家。 研究经历:在国外研修期间,对垂体瘤的克隆分析研究颇深,在著名杂志《CANCER》上首先报道多激素分泌性垂体泌乳素腺瘤大多数起源于单克隆,并在《Hormone Research》杂志上发表有关垂体TSH腺瘤合并增生的临床及基础研究结果,上述研究对垂体腺瘤的发生研究具有一定的指导意义,为此获日本东北医学会特别奖,获中华医学会联合主办中青年奖学金优秀论文二等奖。2014年卫计委卫生行业专项基金“脑肿瘤分子分类指导个体化诊疗体系的建立和应用推广”项目分课题负责人,后主持国家自然科学基金课题“自杀基因疗法治疗脑胶质瘤的实验研究”,部分成果在第三届中-日-法国际神经外科会议上宣读。目前主要致力于脑胶质瘤和脑转移瘤的临床和基础研究,主持多项国家级、省级、院校及医院课题,并且作为主要研究者指导并开展20余项针对脑胶质瘤的药物临床试验。主持及参与编写《脑胶质瘤技术与进展2011》、《脑肿瘤的化学治疗》、《颅脑肿瘤外科学》、《神经外科诊疗常规》、《中国脑胶质瘤临床管理指南2020》等专著,以及国内多项针对脑胶质瘤的临床诊治指南,主持及参与翻译《脑肿瘤免疫治疗及转化研究》、《中枢神经系统转移性肿瘤》等国外专著,已以第一作者或通讯作者发表SCI论文100余篇,中文核心期刊10余篇。
团队简介
Team Profile
北京协和医院神经外科脑恶性肿瘤团队由马文斌教授和王裕教授共同领导,成员包括6名博士后(2名出站留院,4名在站)、多名硕博士研究生和协和八年制、4加4试点班学生。团队主要致力于脑胶质瘤、脑转移瘤的临床和基础研究,与清华大学、北京航天航空大学、北京交通大学、协和基础医学研究所等院校及机构合作,开展脑胶质瘤多模态影像组学研究、脑胶质瘤发生与耐药研究、植入式肿瘤治疗电场设备研发等研究。
硕士研究生 0 名,博士研究生 10 名
# | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
---|---|---|---|---|---|
1 | 中频电场治疗胶质瘤的植入式设备研发 | 2019-09-01 —— 2022-08-31 | 90万元 | 主持的企业/行业委托重大项目 | 主持人 |
2 | 脑恶性肿瘤精准诊疗关键技术平台的建立和应用 | 2022-10-01 —— 2025-09-01 | 170万 | 主持的企业/行业委托重大项目 | 主持人 |
3 | 针对间质性胶纸母细胞瘤表型特征的双靶点精准治疗研究 | 2019-10-01 —— 2022-09-01 | 20万 | 主持在研的国家或省部级科研项目 | 主持人 |
4 | 颅骨植入式肿瘤电场治疗设备治疗胶质母细胞瘤的体内体外研究 | 2022-01-01 —— 2024-12-31 | 100万 | 主持在研的国家或省部级科研项目 | 主持人 |
# | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
---|---|---|---|---|
1 | Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas | EUROPEAN JOURNAL OF RADIOLOGY | 2019-12-01 | 通讯作者 |
2 | Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses | AGING-US | 2020-07-01 | 通讯作者 |
3 | Development of a nomogram for prognostic prediction of lower-grade glioma based on alternative splicing signatures | Cancer Med-US | 2020-12-01 | 通讯作者 |
4 | F-18-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma | CANCER IMAGING | 2019-08-01 | 通讯作者 |
5 | Thin-Slice Magnetic Resonance Imaging-Based Radiomics Signature Predicts Chromosomal 1P/19q Co-deletion Status in Grade II and III Gliomas | Frontiers in Neurology | 2020-10-01 | 通讯作者 |
6 | Radiomics signature based on FDG-PET predicts proliferative activity in primary glioma | CLINICAL RADIOLOGY | 2019-10-01 | 通讯作者 |
7 | Prognostic Prediction Model for Glioblastoma: A Metabolic Gene Signature and Independent External Validation | Journal of Cancer | 2021-05-01 | 通讯作者 |
8 | Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients | BRIEFINGS IN BIOINFORMATICS | 2021-04-01 | 通讯作者 |
9 | Role of Traditional CHO PET Parameters in Distinguishing IDH, TERT and MGMT Alterations in Primary Diffuse Gliomas | ANNALS OF NUCLEAR MEDICINE | 2021-04-01 | 通讯作者 |
10 | investigation of genetic determinants of glioma immune phenotype by integrative immunogenomic scale analysis | Frontiers in Immunology | 2021-06-01 | 通讯作者 |
11 | Classification of pediatric gliomas based on immunological profiling: implications for immunotherapy strategies | Molecular Therapy-Oncolytics | 2021-02-01 | 通讯作者 |
12 | Comprehensive ability evaluation and trend analysis of patients with malignant intracranial tumors in the perisurgery period | Brain and Behavior | 2021-05-31 | 通讯作者 |
13 | Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma. | JOURNAL OF CELLULAR PHYSIOLOGY | 2022-01-01 | 通讯作者 |
14 | Clinical updates on gliomas and implications of the 5th edition of the WHO classification of central nervous system tumors | Frontiers in Oncology | 2023-03-14 | 通讯作者 |
15 | An online survival predictor in glioma patients using machine learning based on WHO CNS5 data | Frontiers in Neurology | 2023-05-19 | 通讯作者 |
16 | Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023-05-29 | 通讯作者 |
17 | Spotlights on adult patients with pediatric-type diffuse gliomas in accordance with the 2021 WHO classification of CNS tumors | Frontiers in Neuroscience | 2023-05-05 | 通讯作者 |
18 | Prognostic Prediction Model for Glioblastoma: A Ferroptosis-Related Gene Prediction Model and Independent External Validation | Journal of Clinical Medicine | 2023-02-08 | 通讯作者 |
19 | Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma | NEURO-ONCOLOGY | 2023-01-19 | 通讯作者 |
20 | Feasibility of evaluating the histologic and genetic subtypes of WHO grade II-IV gliomas by diffusion-weighted imaging | BMC NEUROSCIENCE | 2022-12-05 | 通讯作者 |
21 | Prognostic Value of Choline and Other Metabolites Measured Using 1H-Magnetic Resonance Spectroscopy in Gliomas: A Meta-Analysis and Systemic Review | Metabolites | 2022-12-05 | 通讯作者 |
22 | Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma | Cell Communication and Signaling | 2023-04-12 | 通讯作者 |
23 | Cytomegalovirus and Glioblastoma: A Review of the Biological Associations and Therapeutic Strategies | Journal of Clinical Medicine | 2022-09-04 | 通讯作者 |
24 | Palliative care for patients with glioma: A recent scientometric analysis of the Web of Science in 2022 | Frontiers in Oncology | 2022-12-13 | 通讯作者 |
25 | Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis | PHARMACOLOGICAL RESEARCH | 2022-08-11 | 通讯作者 |
26 | Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy | Journal of Hematology & Oncology | 2022-10-25 | 通讯作者 |
27 | Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress | Frontiers in Oncology | 2021-08-24 | 通讯作者 |
28 | NTRK fusions and TRK inhibitors: potential targeted therapies for adult glioblastoma. | Frontiers in Oncology | 2020-11-01 | 通讯作者 |
29 | Effects of oncolytic viruses and viral vectors on immunity in glioblastoma | GENE THERAPY | 2020-10-01 | 通讯作者 |
30 | Optimal Therapies for Recurrent Glioblastoma: A Bayesian Network Meta-Analysis | Frontiers in Oncology | 2021-03-01 | 通讯作者 |
31 | PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma clinical studies,challenges and potential | Human Vaccines &Immunotherapeutics | 2020-07-01 | 通讯作者 |
32 | The effect of operations in patients with recurrent diffusse lowgrade glioma :A qualitative systematic review | Clinical Neurology and Neurosurgery | 2020-05-01 | 通讯作者 |
33 | Pretreatment Geriatric Assessments of Elderly Patients with Glioma: Development and Implications | Aging and Disease | 2020-03-15 | 通讯作者 |
34 | Validation of the prognostic value of 9-gene ATE score for IDH wild-type glioblastoma | NEURO-ONCOLOGY | 2021-05-01 | 通讯作者 |
35 | IFN-γ Triggered IFITM2 Expression to Induce Malignant Phenotype in Elderly GBM | JOURNAL OF MOLECULAR NEUROSCIENCE | 2023-10-27 | 通讯作者 |
36 | Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors | Frontiers in Oncology | 2023-07-06 | 通讯作者 |
37 | Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors. | Cancer Medicine | 2023-09-01 | 通讯作者 |
38 | Clinical roles of EGFR amplification in diffuse gliomas: a real-world study using the 2021 WHO classification of CNS tumors | Frontiers in Neuroscience | 2024-02-26 | 通讯作者 |
39 | Artificial neural network identified a 20-gene panel in predicting immunotherapy response and survival benefits after anti-PD1/PD-L1 treatment in glioblastoma patients | Cancer Medicine | 2024-05-18 | 通讯作者 |
40 | Identification of TMZ resistance‐associated histone post‐translational modifications in glioblastoma using multi‐omics data | CNS Neuroscience & Therapeutics | 2024-02-04 | 通讯作者 |
41 | Validation of the prognostic value of 9-gene ATE score for IDH wild-type glioblastoma | NEURO-ONCOLOGY | 2021-05-01 | 通讯作者 |
42 | Glioma hexokinase 3 positively correlates with malignancy and macrophage infiltration | METABOLIC BRAIN DISEASE | 2024-04-30 | 通讯作者 |
43 | 贝伐珠单抗对复发性高级别胶质瘤患者的疗效的单中心研究 | 中华神经医学杂志 | 2021-02 | 通讯作者 |
44 | 老年高级别胶质瘤的临床特点和治疗 | 中华神经外科 | 2020-02 | 通讯作者 |
45 | 脑转移瘤患者单纯手术治疗与手术联合术后脑部放疗对比分析 | 中国现代神经疾病杂志 | 2021-02 | 通讯作者 |
46 | 基于美国SEER数据库的儿童胶质瘤临床特点和预后分析 | 中国现代神经疾病杂志 | 2021-03 | 通讯作者 |
47 | Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study | Cancer medicine | 2024-07 | 通讯作者 |
48 | Programmed cell death disrupts inflammatory tumor microenvironment (TME) and promotes glioblastoma evolution | Cell communication and signaling | 2024-06 | 通讯作者 |
49 | The molecular signature and prognosis of glioma with preoperative intratumoral hemorrhage: a retrospective cohort analysis | BMC neurology | 2024-06 | 通讯作者 |
# | 获奖证书编号 | 奖项名称 | 获奖级别 | 获奖类别 | 获奖等级 | 获奖日期 | 颁奖单位 | 本单位是否为第一完成单位 | 完成单位排名 | 本人排序 | 备注 |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 202202011P401 | 脑胶质瘤全病程管理体系的建立及应用推广 | 省部级 | 北京医学科技奖 | 二等奖 | 2023-07-26 | 北京医学会 | 是 | 1 | 1 |
# | 成果类型 | 项目/专利/新品种名称 |
---|---|---|
1 | 出版高水平专著 | 脑肿瘤免疫治疗及转化研究 |
2 | 出版高水平专著 | 中国脑胶质瘤临床管理指南2020 |
3 | 出版高水平专著 | 颅脑肿瘤外科学 |
4 | 作为主创人员获得授权的发明专利和新品种 | 植入式电极装置及其制备方法 |
5 | 获得省部级及以上科研奖励 | 2022年北京医学科技奖二等奖 |